{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"title":"Doubling"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"13"}]}],"title":"Less than doubling"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Participants with \\>= 2 fold increase in circulating PBSC's in blood and in apheresis collections in up to 4-days collection","groups":[{"description":"Group A: Bortezomib 1.3 mg/m2 in the evening after completion of 5 day mobilization with G-CSF","id":"OG000","title":"Group A: Bortezomib 1.3 mg/m2"},{"description":"Group B Bortezomib 1/3 mg/m2 on day 4 of 5 day GCSF mobilizati","id":"OG001","title":"Group B Bortezomib 1/3 mg/m2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Evaluable patients","reportingStatus":"POSTED","timeFrame":"Up to 6 months","title":">= 2 Fold Increase in Circulating PBSC's","type":"PRIMARY","unitOfMeasure":"Participants"}